By a News Reporter-Staff News Editor at Biotech Week -- New research on Oncology is the subject of a report. According to news reporting out of Garching, Germany, by NewsRx editors, research stated, "The development of effective therapeutic strategies against prostate cancer bone metastases has been impeded by the lack of adequate animal models that are able to recapitulate the biology of the disease in humans. Bioengineered approaches allow researchers to create sophisticated experimentally and physiologically relevant in vivo models to study interactions between cancer cells and their microenvironment under reproducible conditions."
Our news journalists obtained a quote from the research from Technical University, "The aim of this study was to engineer a morphologically and functionally intact humanized organ bone which can serve as a homing site for human prostate cancer cells. Transplantation of biodegradable tubular composite scaffolds seeded with human mesenchymal progenitor cells and loaded with rhBMP-7 resulted in the development of a chimeric bone construct including a large number of human mesenchymal cells which were shown to be metabolically active and capable of producing extracellular matrix components. Micro-CT analysis demonstrated that the newly formed ossicle recapitulated the morphological features of a physiological organ bone with a trabecular network surrounded by a cortex-like outer structure. This microenvironment was supportive of the lodgement and maintenance of murine haematopoietic cell clusters, thus mimicking a functional organ bone. Bioluminescence imaging demonstrated that luciferase-transduced human PC3 cells reproducibly homed to the humanized tissue engineered bone constructs, proliferated, and developed macro-metastases. This model allows the analysis of interactions between human prostate cancer cells and a functional humanized bone organ within an immuno-incompetent murine host."
According to the news editors, the research concluded: "The system can serve as a reproducible platform to study effects of therapeutics against prostate cancer bone metastases within a humanized microenvironment."
For more information on this research see: Species-specific homing mechanisms of human prostate cancer metastasis in tissue engineered bone. Biomaterials, 2014;35(13):4108-4115. Biomaterials can be contacted at: Elsevier Sci Ltd, The Boulevard, Langford Lane, Kidlington, Oxford OX5 1GB, Oxon, England. (Elsevier - www.elsevier.com; Biomaterials - www.elsevier.com/wps/product/cws_home/30392)
Our news journalists report that additional information may be obtained by contacting B.M. Holzapfel, Technical University of Munich, Inst Adv Study, D-85748 Garching, Germany. Additional authors for this research include F. Wagner, D. Loessner, N.P. Holzapfel, L. Thibaudeau, R. Crawford, M.T. Ling, J.A. Clements, P.J. Russell and D.W. Hutmacher (see also Oncology).
Keywords for this news article include: Tissue Engineering, Biomedical Engineering, Biomedicine, Europe, Germany, Garching, Oncology, Therapeutics, Bone Research, Bioengineering, Prostate Cancer, Prostatic Neoplasms
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC